MX2018008302A - Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. - Google Patents

Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.

Info

Publication number
MX2018008302A
MX2018008302A MX2018008302A MX2018008302A MX2018008302A MX 2018008302 A MX2018008302 A MX 2018008302A MX 2018008302 A MX2018008302 A MX 2018008302A MX 2018008302 A MX2018008302 A MX 2018008302A MX 2018008302 A MX2018008302 A MX 2018008302A
Authority
MX
Mexico
Prior art keywords
antibody
therapeutic anti
therapeutic
present
therapeutic applications
Prior art date
Application number
MX2018008302A
Other languages
English (en)
Inventor
Spits Hergen
Maria Wilhelmina Van Helden Paula
POS Wouter
Schotte Remko
Michiel GO Danïel
Wagner Koen
FATMAWAIT Christien
Christian Villaudy Julien
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of MX2018008302A publication Critical patent/MX2018008302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona nuevos compuestos de unión y aplicaciones terapéuticas de los mismos.
MX2018008302A 2016-01-08 2017-01-06 Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. MX2018008302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16150698 2016-01-08
PCT/NL2017/050003 WO2017119811A1 (en) 2016-01-08 2017-01-06 Therapeutic anti-cd9 antibody

Publications (1)

Publication Number Publication Date
MX2018008302A true MX2018008302A (es) 2018-09-21

Family

ID=55085581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008302A MX2018008302A (es) 2016-01-08 2017-01-06 Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.

Country Status (13)

Country Link
US (2) US11136407B2 (es)
EP (1) EP3400245A1 (es)
JP (1) JP7036729B2 (es)
KR (1) KR20180101483A (es)
CN (1) CN108699150B (es)
AU (2) AU2017205900B2 (es)
BR (1) BR112018013801A2 (es)
CA (1) CA3010223A1 (es)
EA (1) EA201891299A1 (es)
IL (1) IL260347A (es)
MX (1) MX2018008302A (es)
SG (1) SG11201805649UA (es)
WO (1) WO2017119811A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2576742A (en) * 2018-08-29 2020-03-04 Lorico Aurelio Antigen-binding fragment and aptamer for binding CD9 and therapeutic uses
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
US20230151109A1 (en) * 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9
EP4103611B1 (en) * 2020-02-13 2024-03-27 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
EP4103609A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
US20230151108A1 (en) * 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3405739B2 (ja) 1991-04-12 2003-05-12 武田薬品工業株式会社 モノクローナル抗体、ポリペプチド及びその製造法
ATE182178T1 (de) 1991-04-12 1999-07-15 Takeda Chemical Industries Ltd Monoklonaler antikörper, polypeptide und deren herstellung
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
WO2004007685A2 (en) * 2002-07-12 2004-01-22 The University Of Tennessee Research Foundation Methods of modifying behavior of cd9-expressing cells
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
MX2010001637A (es) 2007-08-17 2010-03-15 Hoffmann La Roche Mediacion de citotoxicidad de celulas que evidencian la expresion superficial de cd9.
US20100158801A1 (en) 2008-12-23 2010-06-24 Young David S F Methods for the treatment of acute myeloid leukemia
KR101008314B1 (ko) 2008-03-27 2011-01-14 성균관대학교산학협력단 Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도
EP2207803B1 (en) 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
CA2860163A1 (en) * 2011-12-26 2013-07-04 Shionogi & Co., Ltd. Monoclonal antibody for detecting exosomes
WO2014142752A1 (en) * 2013-03-12 2014-09-18 Agency For Science, Technology And Research Pre-eclampsia biomarkers
JP6159011B2 (ja) 2013-03-15 2017-07-05 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体

Also Published As

Publication number Publication date
EP3400245A1 (en) 2018-11-14
JP2019509019A (ja) 2019-04-04
CN108699150B (zh) 2022-08-09
AU2017205900A1 (en) 2018-07-19
AU2017205900B2 (en) 2024-02-15
EA201891299A1 (ru) 2019-01-31
BR112018013801A2 (pt) 2018-12-11
JP7036729B2 (ja) 2022-03-15
US20220064323A1 (en) 2022-03-03
WO2017119811A1 (en) 2017-07-13
NZ744187A (en) 2021-08-27
AU2024203171A1 (en) 2024-05-30
KR20180101483A (ko) 2018-09-12
US20190023803A1 (en) 2019-01-24
US11136407B2 (en) 2021-10-05
US11999793B2 (en) 2024-06-04
CN108699150A (zh) 2018-10-23
IL260347A (en) 2018-08-30
CA3010223A1 (en) 2017-07-13
SG11201805649UA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12017502180A1 (en) Tau-binding antibodies
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
CR20230163A (es) ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
MX2019001878A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
NZ725568A (en) Modified j-chain
PH12017502207A1 (en) Tau-binding antibodies
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
TW201613963A (en) Anti-JAGGED1 antibodies and methods of use
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12017502028A1 (en) Vortioxetine pyroglutamate
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2015010789A (es) Anticuerpos anti-pcsm.
EA201792492A1 (ru) Aml-антигены и их применение
NZ744340A (en) Anti-jagged1 antibodies and methods of use